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The lysophospholipids, sphingosine-1-phosphate (S1P), lysophosphatidic acid (LPA), sphingosylphosphorylcholine (SPC) and lysophos-
phatidylcholine (LPC), activate diverse groups of G-protein-coupled receptors that are widely expressed and regulate decisive cellular functions.
Receptors of the endothelial differentiation gene family are activated by S1P (S1P1–5) or LPA (LPA1–3); two more distantly related receptors are
activated by LPA (LPA4/5); the GPR3/6/12 receptors have a high constitutive activity but are further activated by S1P and/or SPC; and receptors of
the OGR1 cluster (OGR1, GPR4, G2A, TDAG8) appear to be activated by SPC, LPC, psychosine and/or protons. G-protein-coupled
lysophospholipid receptors regulate cellular Ca2+ homoeostasis and the cytoskeleton, proliferation and survival, migration and adhesion. They
have been implicated in development, regulation of the cardiovascular, immune and nervous systems, inflammation, arteriosclerosis and cancer.
The availability of S1P and LPA at their G-protein-coupled receptors is regulated by enzymes that generate or metabolize these lysophospholipids,
and localization plays an important role in this process. Besides FTY720, which is phosphorylated by sphingosine kinase-2 and then acts on four
of the five S1P receptors of the endothelial differentiation gene family, other compounds have been identified that interact with more ore less
selectivity with lysophospholipid receptors.
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Ligands at G-protein-coupled receptors (GPCR) are
structurally as diverse as biogenic amines, amino acids,
nucleotides, photons, peptides, glycoproteins, odorants, ions,
and lipids (see historic review by [1]). Many classes of lipid
mediators are now recognized to act as agonists at GPCRs,
among them the cyclooxygenase and lipoxygenase products
of arachidonic acid, the cannabinoids, platelet-activating
factor, and the lysophospholipids (for overview and nomen-
clature, see [2,3]). Lysophospholipid mediators can have a
glycerol or sphingoid backbone and are characterized by
having a single carbon chain and a polar headgroup. These
structural features render them more hydrophilic and versatile
than their corresponding phospholipids. Among several
lysophospholipids for which a biological action has been
demonstrated, lysophosphatidic acid (LPA) and sphingosine-
1-phosphate (S1P) have been characterized in greatest detail
so far. The last decade has seen an enormous increase in
knowledge about lysophospholipid receptors and metabolism,
as well as biological functions of S1P and LPA. A family of
five S1P-GPCRs and three related LPA-GPCRs (for review,
see [4–8]), three not related GPCRs with high constitutive
activity that are nevertheless further activated by S1P and
sphingosylphosphorylcholine (SPC) [9], and two more LPA-
GPCRs [10,11] have been identified so far. Furthermore, a
group of GPCRs that are differentially activated by protons
and by the lysophospholipids, SPC, lysophosphatidylcholine
(LPC) and psychosine have been described (reviewed in [12–
14]). It cannot be excluded that there might be other
lysophospholipid receptors among the remaining ∼150
orphan GPCRs of the human genome.
Lysophospholipid GPCRs are widely expressed and it has
been suggested that all cells in mammals respond in one way
or another to LPA and S1P [5]. Lysophospholipid GPCRs
regulate a broad range of cellular functions: cell proliferation
and survival, migration and chemotaxis, cytoskeletal archi-
tecture, cell-cell-contacts and adhesion, Ca2+ homoeostasis
and Ca2+-dependent functions. This results in a particular
impact of lysophospholipids on angiogenesis and lymphocyte
trafficking, development of the nervous system, cancer
growth and metastasis, as well as inflammation and arterio-
sclerosis [6,15–18].
Understandably, lysophospholipid GPCRs are promising
pharmacological targets [19,20]. The first drug interacting
with S1P-GPCRs, FTY720 [21], also named fingolimod, is
undergoing clinical trials for prevention of kidney graft
rejection and multiple sclerosis. Other, receptor subtype-selective drugs for S1P- and LPA-GPCRs are emerging,
increasing the potential medicinal importance of this research
field.
This review will provide a general overview on established
and still controversial lysophospholipid GPCRs, their signal
transduction pathways, cellular and biological actions, with a
focus on recent findings. Furthermore, our understanding of
how S1P and LPA are delivered to their respective receptors,
and how their action is terminated, has been substantially
increased and is reviewed here in detail. Finally, the emerging
lysophospholipid pharmacology will be presented and dis-
cussed. We apologize that important work will not be mentioned
here because of space limitations.
2. Established and controversial lysophospholipid receptors
and their signalling pathways
2.1. S1P- and LPA-GPCRs of the endothelial differentiation
gene family
In 1996, a GPCR, named ventricular zone gene-1, that was
expressed in cortical neurogenic regions of the developing
mouse brain, was identified and shown to be a LPA receptor
[22]. Soon thereafter, a related orphan GPCR, discovered in
1990 as a transcript induced during differentiation of endothe-
lial cells and named endothelial differentiation gene-1 (EDG-1)
[23], was shown to be activated by S1P [24–26]. These
groundbreaking discoveries led to rapid deorphanization of
altogether eight homologous GPCRs, five activated by S1P and
three activated by LPA, of the so-called EDG receptor family
that had been named after EDG-1. These GPCRs are now
named according to IUPHAR nomenclature after their main
physiological ligand and numbered in the order of discovery
[2].
S1P1–3 and LPA1–3 are ubiquitously expressed. There are
comprehensive recent reviews on these receptors available [4–
6,8,20,27–29]. Therefore, signalling of S1P1–3 and LPA1–3 is
summarized here only in brief, see also Table 1. The S1P1
receptor is unique because it is apparently coupled only to Gi
proteins, by which it nevertheless regulates many cellular
functions, e.g., extracellular signal-regulated kinase (ERK)
activation and proliferation, Akt activation and survival, and,
most important, Rac activation and migration. Crucial functions
of S1P1 such as stimulation of angiogenesis and lymphocyte
trafficking are apparently based on its ability to stimulate
migration [30,31]. S1P2 is coupled to Gi, Gq and G12/13 proteins
and activates phospholipase C (PLC), mediates increases in
intracellular Ca2+ concentration ([Ca2+]i) and stimulates ERK.
Table 1
G-protein-coupled lysophospholipid receptors
Receptor Endogenous ligand(s)
and activators
Main tissue distribution Main signal transduction pathways and cellular effects Ref.
S1P1 S1P,
dihydro-S1P
>SPC
Ubiquitous Gi/o ERK↑, PI3K/Akt↑,
Rac↑, AC↓
Migration, proliferation, survival,
cell–cell-contacts, angiogenesis,
lymphocyte trafficking
Reviews:
[4–6,8,20,
27–29]
S1P2 Ubiquitous Gi/o, Gq,
G12/13
PLC↑, [Ca2+]i↑, ERK↑,
Rho↑, Rac↓, Cdc42
Migration ↓,
contribution to vascular
development, differentiation of SMC
S1P3 Ubiquitous Gi/o, Gq,
G12/13
PLC↑, [Ca2+]i↑, Rho↑,
Rac↑, ERK↑, Akt↑
Heart rate ↓,
contribution to vascular
development, NO-dependent
vasorelaxation
S1P4 Phyto-S1P,
dihydro-S1P
>S1P>SPC
Lymphoid and
haematopoietic tissue
Gi/o, G12/13 PLC↑, [Ca
2+]i↑, ERK↑,
Rho↑↓, Cdc42↑
Migration ↑↓,
proliferation and
cytokine secretion in T cell lines ↓
[44,47,48]
S1P5 S1P, dihydro-S1P Brain, white matter
tracts, oligodendrocytes;
skin
Gi/o, G12/13 AC↓, ERK↓, JNK↑ Proliferation ↓,cell rounding,
process retraction in OPC, survival
of mature ODC
[53,56,57]
LPA1 LPA Ubiquitous Gi/o, Gq,
G12/13
AC↓, ERK↑, Akt↑, Rho↑,
Rac↑, PLC↑, [Ca2+]i↑
Proliferation ↑, survival ↑ (e.g. of
Schwann cells), neurite retraction,
brain development, olfaction
Reviews:
[4–6,8,27,
226]
LPA2 LPA Ubiquitous Gi/o, Gq,
G12/13
Rho ↑, PLC↑, [Ca2+]i↑,
ERK↑, Akt↑, AC↓
Proliferation, survival
LPA3 LPA; preference for
unsaturated acyl
chains
Ubiquitous Gi/o, Gq PLC↑, [Ca
2+]i↑, ERK↑,
AC↑ ↓
Implantation (via COX-2) and
embryo spacing in mice
P2Y9/GPR23
(LPA4)
LPA Low level in many tissues,
high levels in ovary
AC↑, [Ca2+]i↑ [10]
GPR63 (LPA5) LPA Low level in many tissues,
high levels in small
intestine and DRG
Gq, G12/13 AC↑, [Ca
2+]i↑ Stress fibre formation, neurite
retraction
[11]
GPR3 Const. activity, S1P Rodent oocytes, diverse
EC and VSMC
Gs, Gi/o AC↑, [Ca
2+]i↑ Meiotic arrest of rodent oocytes [9,60–64]
GPR6 Const. activity, S1P Mouse brain, diverse
EC and VSMC
Gs, Gi/o AC↑, [Ca
2+]i↑
GPR12 Const. activity,
S1P or SPC
Mouse brain, diverse
EC and VSMC, rodent
oocytes
Gs, Gi/o AC↑, [Ca
2+]i↑ Increase in synaptic contacts in rat
cortical neurons, meiotic arrest of
rodent oocytes
OGR1 SPC, proton Widely; e.g. bone Gi/o, other L: [Ca
2+]i↑, ERK↑
P: IP↑, AC↑
Inhibition of proliferation,
osteoclastogenesis
Reviews:
[13,14]
GPR4 SPC, LPC, proton Widely; e.g., endothelial
cells; overexpressed in
cancer cells
Gi/o, other L: [Ca
2+]i↑, ERK↑
C: ERK↓
P: AC↑
Migration, angiogenesis, impairment
of endothelial barrier function
Articles:
[80,82–89,
91,227]
G2A LPC, SPC, proton (?) Lymphoid tissues,
lymphocytes, macrophages
Gi/o, Gq,
Gs, G13
L: [Ca2+]i↑, ERK↑
C: IP↑, AC↑, Rho↑,
stress fibre formation ↑
P: IP↑ (?)
Migration, apoptosis, suppression
of autoimmunity
TDAG8 Psychosine,
gluco-psychosine,
lysosulfatide, proton
Lymphoid tissues,
T cells; overexpressed
in cancer cells
Gi/o, other L: [Ca
2+]i↑, AC↓
P: AC↑, Rho↑, stress
fibre formation ↑
Formation of multinuclear cells (?),
apoptosis
Abbreviations used in the table: AC, adenylyl cyclase; C, constitutive signalling by transfected receptors; const. activity, constitutive activity; COX, cyclooxygenase;
IP, inositol phosphates; L, activities induced by lipid ligand; ODC, oligodendrocytes; OPC, oligodendrocyte precursors; P, activities induced by protons; SMC, smooth
muscle cells. For further references, see text.
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thereby promoting cellular stress fibre formation and inhibiting
migration of many cell types, including melanoma cells [32,33].
Similar to S1P2, S1P3 is coupled to Gi, Gq and G12/13 proteins.
This receptor strongly activates PLC and induces [Ca2+]i
increases, ERK, Rho and Rac activation. S1P3, via [Ca
2+]i
increases and Akt stimulation, induces NO synthase activation
and vasorelaxation [34]. S1P3 furthermore via Gi activates G-
protein-regulated inward rectifier potassium channels, therebyslowing the heart rate [35–37]. Looking at signalling by S1P-
GPCRs in general, there appears to be redundancy as well as
functional antagonism (see discussion in [29]). Redundancy
probably prevents major symptoms in mice in which either
S1P2 or S1P3 has been deleted [38,39]. Functional antagonism
is observed for example with S1P1 and S1P2, which strongly
stimulate or inhibit cell migration, respectively (reviewed in
[16]), or with S1P5 and the other S1P-GPCRs, because S1P5
uniquely inhibits ERK and cell proliferation.
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to couple via Gi, Gq and G12/13 proteins to many signalling
pathways [17]. These receptors stimulate PLC and induce
[Ca2+]i increases, activate Ras and ERK and stimulate
proliferation, and via Akt promote cell survival. LPA-GPCRs
have furthermore a strong impact on cytoskeleton and migration
by coupling to both Rho and Rac. In heterologous expression
systems, GPCRs might be able to couple to pathways which are
not preferred by endogenous receptors. Considering knockout
approaches, it was suggested that the main, but not only,
signalling pathways of endogenous LPA-GPCR might be the
following: LPA1, Gi-dependent signalling; LPA2, G12/Rho-
regulated cytoskeleton rearrangements and cell rounding; LPA3,
Gq-mediated PLC activation and [Ca
2+]i increases [27]. Further
studies are needed for assigning endogenous LPA receptor
subtypes to specific signal transduction pathways.
Much less is known about the S1P4 and S1P5 receptors.
S1P4 was isolated from dendritic cells and is expressed in
lymphoid and haematopoietic cells and tissues [40]. This
receptor differs from the other S1P-GPCRs of the EDG
family with respect to its binding pocket [41]. This is
reflected by a higher affinity for phyto-S1P and dihydro-S1P
than S1P [42,43]. S1P4 couples to Gi and G12/13 proteins, but
not to Gq and G15/16, at least as tested with a GTP
photoaffinity label [44]. S1P4 via Gi stimulated ERK, PLC
and [Ca2+]i increases [45,46]. It activated Rho and rearranged
the cytoskeleton in one study [44], while it did not activate
Rho or Rac in another study, but stimulated Cdc42 and cell
migration [47], both studies in transfected CHO cells. These
inconsistencies could probably be due to problems in
trafficking of overexpressed S1P4 to the plasma membrane
[47]. When transfected into T cell lines devoid of endogenous
S1P-GPCRs, S1P4 had no influence on migration and
chemotaxis, but inhibited cell growth and secretion of
proinflammatory cytokines [48]. Interestingly, FTY720,
which caused internalization of S1P1, did not internalize
S1P4 [49], although phosphorylated FTY720 activates both
receptors [50,51].
S1P5 was originally cloned from PC12 cells, where its
mRNA was downregulated by nerve growth factor (NGF)
[52]. S1P5 expressed in CHO cells activated Gαi/o and Gα12
proteins, but not Gαs or Gαq, as shown by GTPγS binding to
immunoprecipitated G-proteins [53]. S1P5 furthermore
mediated inhibition of adenylyl cyclase [53,54], and interest-
ingly had a negative impact on ERK and cell growth, whereas
it activated JNK [53]. Neither activation of PLC nor increases
in [Ca2+]i were observed with S1P5 [53]. Overexpressed S1P5
inhibited ERK and induced cell rounding even in the absence
of exogenous S1P, indicating constitutive activity [55]. In situ
hybridization studies and histochemical analysis with a
specific antibody revealed its abundant expression in white
matter tracts of rodent brain [54,56,57]. The S1P5 antibody
and mRNA probes specifically stained all developmental
stages of oligodendrocytes [56,57]. In differentiated oligoden-
drocytes which predominantly express the two lysopho-
spholipid receptors, LPA1 and S1P5, both LPA and S1P
induced activation of ERK in a pertussis toxin (PTX)-insensitive manner [58], indicating that signalling by
endogenous S1P5 in its natural environment might be
different from that observed with the transfected receptor.
Furthermore, S1P5 via Rho kinase mediated process retraction
in pre-oligodendrocytes but not in mature oligodendrocytes,
while S1P5 via Gi and Akt enhanced survival of mature
oligodendrocytes but not of pre-oligodendrocytes [57]. These
results suggest that the functional role of the receptor is
dependent on the cellular differentiation status, and that S1P5
plays a role in brain myelinization. However, mice in which
S1P5 was genetically deleted had no apparent behavioural
deficits, and their neuropathological examination did not
reveal an apparent myelin deficiency [57].
2.2. GPR3, GPR6, GPR12
These GPCRs form a cluster with high similarity to each
other and ∼40% similarity to EDG, cannabinoid and
melatonin receptors [59]. Heterologous expression of GPR3,
GPR6 and GPR12 led to strong activation of adenylyl cyclase
in the absence of exogenous ligand. However, members of
this GPCR cluster were also shown to respond to S1P and/or
SPC [9,60–62]. Transfection of human GPR3, GPR6 and
GPR12 enhanced S1P-stimulated [Ca2+]i increases in HEK-
293 cells; these responses were caused by nanomolar S1P and
fully inhibited by PTX. S1P furthermore induced internaliza-
tion of GPR6 [9]. Other authors expressed mouse GPR12
with a signal peptide for improved membrane insertion, and
observed that it enhanced the background [Ca2+]i increases
induced by SPC with an EC50 of 66 nM, while S1P was
clearly less potent [60]. Mouse GPR6, however, responded
preferentially to S1P like the human receptor [61]. Further-
more, both GPR6 and GPR12 via Gi mediated activation of
G-protein-gated inwardly rectifying K+ currents in transfected
Xenopus oocytes by S1P and SPC, respectively, and GPR6
mediated ERK activation by S1P [60,61]. GPR6 and GPR12
are strongly expressed in mouse brain. GPR12 mRNA
transcripts were detected in all areas of the developing
mouse central nervous system, especially the cerebral cortex,
and expression of this receptor was upregulated at the stage in
which neurons start to migrate and differentiate. Other than
LPA1, GPR12 is apparently not expressed in the ventricular
zone where proliferation of neuronal precursors takes place.
In adult mouse brain, GPR12 was predominantly detected in
the forebrain region where major constituents of the limbic
system, e.g., hippocampus, were labelled [60]. A functional
analysis of endogenously expressed GPR12 was performed in
the hippocampal cell line HT22 and in embryonic cerebral
cortical neurons, both of which do not express the high-
affinity SPC-GPCRs, GPR4 and OGR1. SPC stimulated
proliferation and cell clustering of the hippocampal cells, and
increased synaptic contacts and synaptophysin expression in
the embryonic cortical neurons [60].
There are also reports showing that GPR3, GPR6 and
GPR12 play important roles outside the nervous system. For
example, all three receptors are abundantly expressed in diverse
endothelial and vascular smooth muscle cells, and fluid shear
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umbilical vein endothelial cells [62]. Interestingly, GPR3 and
GPR12 are highly expressed in mouse oocytes, but not in the
surrounding somatic cells, and these receptors mediate a signal
that maintains the oocytes in meiotic arrest [63,64]. Mammalian
oocytes stay in prophase arrest until ovulation is triggered by
luteotropin. This depends on an unknown signal from the
surrounding somatic cells, since removal of oocytes from antral
follicles resumes meiosis. Furthermore, various lines of
evidence show that high cAMP levels are essential for meiotic
arrest (for review, see [65]). Spontaneous oocyte maturation in
vitro was inhibited by injection of GPR3 and GPR12 mRNA,
while antisense oligonucleotides caused meiotic resumption
[64]. Furthermore, oocytes from GPR3 knockout mice
spontaneously resume meiosis within antral follicles in vivo,
independently of an increase in luteotropin, and this phenotype
was reversed by injection of GPR3 mRNA into the oocytes
[63]. Unexpectedly, GPR3-deficient mice were fertile, but they
displayed progressive reduction in litter size, indicating
premature ovarian failure due to early oocyte aging [66].
These data support previous findings, namely that oocyte loss in
adult female mice induced by radiation was completely
prevented by in vivo therapy with S1P [67,68]. Finally, a role
for lipid ligands in meiotic arrest was shown by demonstrating
that in vitro maturation of oocytes was delayed by SPC and S1P
[64].
2.3. LPA4 and LPA5
In 2003, a novel LPA-GPCR, P2Y9/GPR23, now named
LPA4, was detected that was structurally distant from LPA
receptors of the EDG family [10]. Very recently, it was
demonstrated that the orphan GPR92 is activated by LPA, and it
was named LPA5 [11]. These two receptors, LPA4 and LPA5,
have ∼35% amino acid identity with each other and are thus
more related to each other than to the LPA-EDG receptors.
LPA4 shares only 20-24% amino acids with LPA1, LPA2 and
LPA3, which share 50–57% of their amino acids [6,10]. When
transfected into no- or low-background cells, LPA4 preferen-
tially bound 1-oleoyl-LPAwith a KD of ∼50 nM, and this LPA
species also preferentially activated a reporter gene in LPA4
expressing cells, while LPA species with saturated or shorter
acyl chains were less affine and active, and other lysopho-
spholipids did not compete with LPA binding. Functionally, the
receptor mediated increases in cAMP and [Ca2+]i [10]. The
GPR92/LPA5 receptor mediated stress fibre formation in
RH7777 rat hepatoma cells, neurite retraction via Gα12, Gα13
and Rho kinase in B193 neuroblastoma cells, and furthermore
stimulated increases in cAMP and, via Gαq, elevated [Ca
2+]i
[11]. Although both LPA4 and LPA5 elevated cAMP levels,
their coupling to Gs proteins remains to be proven. LPA5 was
internalized by LPA but not by S1P, however, its precise ligand
specificity remains to be determined. Low levels of mRNA
transcripts of both LPA4 and LPA5 are abundantly expressed;
high levels of LPA4 were found in ovary, while LPA5 was
strongly expressed in small intestine, spleen, dorsal root
ganglion cells and embryonic stem cells [10,11]. It is temptingto speculate that these two receptors allow the lysophospholipid
LPA to couple to Gs pathways which are not among the
preferred signalling pathways of LPA-EDG receptors.
2.4. Lysophospholipid- and proton-regulated GPCRs
Many cells respond in diverse ways to SPC, LPC,
psychosine and glucopsychosine, and GPCR-dependent as
well as GPCR-independent signalling of these lipids has been
suggested. OGR1, GPR4, G2A and TDAG8 form a cluster of
homologous GPCRs that are candidate high-affinity receptors
for SPC (OGR1, GPR4, G2A), LPC (GPR4, G2A) and
psychosine (TDAG8). Shortly after their first description as
lipid receptors [69–72], crucial binding data could apparently
not be reproduced, thus leading to the retraction of papers
concerning GPR4 and G2A [73,74]. A major proof for SPC as a
ligand at OGR1 and GPR4 had been the observations that
transfection of these receptors enabled SPC to induce [Ca2+]i
increases in otherwise non-responsive cells, and that SPC
caused internalization of plasma membrane localized ORG1-
and GPR4-GFP fusion proteins [69,70]. However, other authors
did not observe internalization of GPR4 upon stimulation with
SPC, although internalization of OGR1 by SPC was confirmed
[75]. Transfected GPR4 was furthermore shown to be
constitutively active, inhibiting ERK in a ligand-independent
manner [75]. Interestingly, in 2003, OGR1 and GPR4 were
described as proton-sensing receptors [76]. Expression of these
receptors rendered otherwise non-responsive cells sensitive to
acidification, with protons stimulating inositol phosphate
production and cAMP accumulation in OGR1- and GPR4-
transfected cells, respectively. The receptors were inactive or
only slightly active at pH 7.6 to 7.8, and strongly activated at pH
7.2 to 7.0. By homology modelling with rhodopsin and
mutational analysis, five histidine residues were identified that
were conserved in ORG1 and GPR4 and required for proton
sensing [76]. It was suggested that hydrogen bonding between
histidines stabilizes the receptors in the inactive state, while
protonation elicits the conformational change into the active
state [76]. Interestingly, proton-induced inositol phosphate
accumulation in OGR1-expressing cells was insensitive to
PTX, while [Ca2+]i increases in response to SPC were PTX-
sensitive [69], suggesting that differential G-protein coupling
could be caused by the two activation mechanisms. Later,
proton sensing was not only confirmed for OGR1 [77], but also
shown for G2A [78] and TDAG8 [79]. Acidification induced
internalization of TDAG8 and stimulated Rho and actin
rearrangement [80]. Comparing the proton sensitivity of the
receptors of the OGR1 cluster, it appeared that G2Awas not as
sensitive as OGR1, GPR4, and TDAG8 [81], which could be
due to lack of critical histidines [13,14]. Most importantly, the
putative lipid agonists failed to activate the GPCRs of the
OGR1 cluster in these studies. In contrast, proton-induced
signalling was inhibited by SPC [77], LPC [78] and psychosine
[79]. For this effect, at least 1 μMof LPC was required to inhibit
proton sensing of G2A, whereas 10 μM were required for clear
inhibition at OGR1 and TDAG8. Psychosine did not activate
TDAG8 or one of the other receptors, but 10 μM psychosine
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TDAG8, OGR1 and GPR4 [79]. To explain the diverse effects
of protons and lipids at GPCRs of the ORG1 cluster, a model
was proposed in which the receptors have two regulatory sites,
one for protons and the other for lipids. The lipids were
suggested to interact with both sites, as agonist and antagonist,
respectively [13,14]. However, this model does not explain why
the putative lipid agonists were sometimes able and sometimes
not to activate GPCRs of the OGR1 cluster. Furthermore, it
remains unclear whether the inhibitory action of lipids on
proton signalling was mediated at all by the GPCRs of question.
The reported controversy could be due at least in part to
artificial coupling of overexpressed receptors, incomplete
plasma membrane insertion of transfected receptors, GPCR
heterodimerization, or artificial cellular backgrounds (see also
discussion in [59]). These difficulties are circumvented when
endogenously expressed receptors are studied in their natural
environment. Such studies indeed suggest a role for lipids in
signalling by GPCRs of the OGR1 cluster. For example, GPR4,
but not OGR1, G2A or TDAG8, was found to be expressed in
diverse endothelial cells, and siRNA knockdown of GPR4
abrogated endothelial tube formation by SPC, but not by S1P or
vascular endothelial growth factor [82]. GPR4 was also required
for SPC-stimulated migration of endothelial cells. Interestingly,
while GPR4-transfected HEK-293 cells responded to pH 7.0
with increase in cAMP, this effect was not observed in
endothelial cells, even if GPR4 was additionally transfected
[82]. Another group showed that siRNA knockdown of GPR4
in endothelial cells inhibited LPC-stimulated decrease in
monolayer resistance, while pH<7.4 did not alter baseline or
LPC-stimulated resistances [83]. On the other hand, OGR1 and
GPR4 were found to be expressed in human aortic smooth
muscle cells, in which acidic pH induced inositol phosphate
production, cAMP formation and prostaglandin I2 secretion.
These effects were inhibited by OGR1-siRNA, but not by
GPR4-siRNA [84]. While these data demonstrate a role for
endogenous OGR1 in proton sensing, it has to be noted that at
least pH 6.8 was required for clear effects, while maximal
stimulation required pH 6.4–6.0. The pH dependence of inositol
phosphate production by endogenous OGR1 in smooth muscle
cells was highly different from that reported by Ludwig et al.,
which was biphasic with a maximum at pH 7.0. The reported
acidic conditions that were required raise the question whether
physiological proton sensing might take place by internalized
receptors in endosomes, especially in the light of confocal data
showing a remarkable amount of receptors in intracellular
compartments [76,81,85]. Accordingly, G2A overexpressed in
T cells or in Swiss 3T3 cells was strongly retained in
endosomes, and LPC specifically induced transport of this
GPCR to the plasma membrane [85]. Furthermore, the recycling
blocker, monensin, blocked LPC-stimulated G2A translocation,
migration and ERK activation, raising the questions whether
LPC acted as an antagonist, stabilizing the plasma membrane
localization, or as an agonist, signalling through membrane
G2A, and what was the signal for translocation in the latter case.
Another study with endogenous OGR1 demonstrated that
this receptor was strongly induced during differentiation ofbone marrow mononuclear cells into osteoclasts, and that
inhibition of OGR1 by antibody or siRNA attenuated
osteoclastogenesis [86]. A possible role of auto- or paracrine
lysophospholipids, however, was not investigated. Endogenous
G2A receptor was studied in a T cell line and in mouse
peritoneal macrophages, and deletion of G2A impaired
migration towards LPC [87,88]. TDAG8 (T cell death-
associated gene-8) was upregulated in glucocorticoid-treated
lymphoma cell lines and primary thymocytes, and psychosine
and glucopsychosine, but not S1P, SPC, LPA or LPC,
enhanced glucocorticoid-induced apoptosis in a manner
dependent on TDAG8 expression [89]. Other authors found
that deletion of TDAG8 fully abrogated proton-induced cAMP
formation in thymocytes, while deletion of G2A had no effect
[81].
Taken together, the present data support the hypothesis that
GPCRs of the OGR1 cluster can be regulated by both specific
lipid agonists and protons. However, the precise molecular
mechanisms, by which dual regulation of these receptors takes
place, remain to be determined. G2A and TDAG8 appear to
play a functional role in migration and apoptosis of immune
cells, while OGR1 and GPR4 are wider expressed and for
example contribute to osteoclastogenesis and angiogenesis,
respectively. Mice in which G2A was genetically deleted were
described in 2001, they suffered from a late-onset autoimmune
syndrome that was attributed to insufficient T cell apoptosis
[90]. Recently, it was reported that TDAG8 knockout mice are
normal in appearance, size and mating, and their immune
functions, including glucocorticoid-induced apoptosis of thy-
mocytes, were not obviously impaired [91]. It was speculated
that TDAG8 could be substituted by G2A in immune cells of
TDAG8 knockout mice.
2.5. Interaction of LPA with peroxisome proliferator-activated
receptor-γ
GPCR independent, intracellular actions have been sug-
gested primarily for S1P [92]. However, in 2003, an
intracellular target for LPA was identified, which was the
nuclear transcription factor, peroxisome proliferator-activated
receptor-γ (PPARγ) [93]. PPARγ controls transcription of
genes that are involved in glucose and fatty acid metabolism,
adipocyte differentiation and inflammation processes in the
vasculature, and is activated by the antidiabetic thiazolidine-
diones [94,95]. As endogenous ligands, anionic fatty acids and
their oxidised derivatives have been described. LPA, but not
phosphatidic acid, competed for binding of the thiazolidine-
dione, rosiglitazone, to PPARγ, and stimulated expression of
PPARγ-controlled genes [93]. Furthermore, LPA-induced
progressive formation of neointima in a rat carotid artery
model was inhibited by a PPARγ antagonist and mimicked by
rosiglitazone [96]. The structure–activity relationship for
neointima formation by LPA analogues in vivo was identical
to that of PPARγ activation in vitro and differed from that
described for LPA-GPCRs. LPA 20:4 upregulated the CD36
scavenger receptor and caused dedifferentiation of cultured
vascular smooth muscle cells that was prevented by PPARγ
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able to enter the cells and reach the intracellular receptor. The
interaction of LPA with PPARγ was furthermore analysed in
preadipocytes, which endogenously express high levels of that
transcription factor [97]. Interestingly, LPA did not increase
transcription of two PPARγ-sensitive genes in a mouse
preadipocyte cell line, but, in contrast, decreased PPARγ2
expression, inhibited the action of rosiglitazone on gene
transcription, and reduced triglyceride accumulation. These
anti-adipogenic actions were not observed in cells from LPA1
knockout mice, indicating that LPA1 can mediate down-
regulation of PPARγ2 [97]. These obvious differences to the
previous studies were ascribed to high expression of ecto-lipidFig. 1. Regulation of S1P availability at G-protein-coupled S1P receptors by localize
sphingosine kinases (SphK) and either dephosphorylated by lipid phosphate phosph
(SPL). SphK1 is a cytosolic enzyme (A) that, upon cellular stimulation, can translocate
acid (PA) production (C) [134, 228]. SphK2 is also cytosolic and was observed at the
found at the plasma membrane. Predominantly SphK2, but also SphK1, can be found
act on so far unknown intracellular target sites, or it can be excreted, probably by one o
can thus be derived from auto- or paracrine secretion. In addition, it may be produce
signals is caused by LPPs, SPPs and S1P lyase. LPPs are plasma membrane-bound e
extracellular levels of LPA and S1P. LPPs, predominantly LPP2 and LPP3, can also
SPPs and S1P lyase are endoplasmic reticulum proteins. The catalytic site of S1P lyase
directed towards the lumen of endoplasmic reticulum. Both SPPs and S1P lyase cont
the sphingomyelin pathway [102]:➀ sphingomyelinase,➁ ceramidase,➂ ceramide sy
sphingomyelin; Cer, ceramide; DAG, diacylglycerol. For additional references, seephosphate phosphatases activity in preadipocytes, preventing
LPA to enter the cells in sufficient concentrations for PPARγ
activation [98].
3. Regulation of lysophospholipid availability at
lysophospholipid receptors
3.1. S1P metabolism: kinases, phosphatases, lyase
The enzymes that generate and degrade S1P are evolutionary
highly conserved among eukaryotes from yeast and plant to
mammals [18,99]. S1P is formed by phosphorylation of
sphingosine by sphingosine kinases, and dephosphorylatedd generation and metabolism of S1P. S1P is formed from sphingosine (SPH) by
atases (LPP) and S1P phosphatases (SPP), or irreversibly cleaved by S1P lyase
to the plasma membrane (B) or to intracellular sites such as sites of phosphatidic
endoplasmic reticulum in serum-depleted cells (D) [124], but so far has not been
in the nucleus (E). S1P, depending on the localization where it is generated, can
r more transport mechanisms (⊗) [157]. Extracellular S1P acting on S1P-GPCRs
d by extracellular SphK1 (F) [159]. Termination of extra- and intracellular S1P
nzymes with their catalytic activity directed to the extracellular space, regulating
be found at the endoplasmic reticulum or other intracellular membranes [134].
is directed towards the cytosol [141], while that of SPPs has been predicted to be
ribute to regulation of extracellular S1P levels [129,132,161]. ➀–➃ Enzymes of
nthase,➃ sphingomyelin synthase. Further abbreviations used in the figure: SM,
text.
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phosphatases (SPPs) (Fig. 1). S1P and sphingosine are in
equilibrium with ceramide, which is a membrane-bound
intracellular mediator with functional roles mostly opposite to
S1P (Fig. 1). An irreversible cleavage of S1P is catalysed by
S1P lyase. For review on sphingolipid metabolism in general
and its subcellular localization, see [18,100–102].
Two mammalian isoforms of sphingosine kinase, SphK1 and
SphK2, with molecular weights of 43 and 65 kDa, respectively,
and a number of alternatively spliced isoforms of SphK1 and
SphK2 that differ at their N-termini have been identified [103–
108] (for review, see [109–111]). The two sphingosine kinase
isoenzymes have distinct kinetic properties and are differen-
tially expressed during development as well as in adult tissues,
which indicates distinct biological functions. Indeed, SphK1
promotes cell growth in many cell types, is upregulated in
tumour cells, protects from apoptosis, and has features of an
oncogene [112–121], whereas SphK2 mediates apoptosis
[108,122–124]. In contrast, mice deficient in either SphK1 or
SphK2 are viable and fertile, while double knockout mice died
during embryogenesis and had no measurable tissue levels of
S1P, suggesting that the two sphingosine kinase isoenzymes can
substitute for each other [125–128].
Particularly SphK1 contributes to extracellular S1P acting on
S1P-GPCRs, and therefore regulation of this enzyme will be
discussed in greater detail below.
The enzymes that dephosphorylate S1P and LPA belong to
a superfamily of lipid phosphatases/phosphotransferases with
a common structural motif and specialized functions, for
review see [129–132]. LPP isoenzymes non-specifically
dephosphorylate phosphatidic acid, LPA, ceramide-1-phos-
phate and S1P to generate diacylglycerol, monoacylglycerol,
ceramide and sphingosine, respectively. Three mammalian
LPP isoforms have been identified, termed LPP1, LPP2 and
LPP3. In addition, there is a family of four LPP-related
proteins, termed LPR or plasticity-related genes (PRG), the
functions of which are not entirely clear. LPP1 and LPP3 are
widely expressed while expression of LPP2 is more restricted
[132]. LPPs are integral membrane proteins with six predicted
transmembrane domains, localized to the plasma membrane,
endoplasmic reticulum and other endomembranes [132]. Their
catalytic centres face the extracellular side of the plasma
membrane or the luminal side of organelles. Two functions
have been attributed to these enzymes: (1) regulation of
extracellular levels of lysophospholipids such as LPA and S1P
by their ecto-phosphatase activity, and (2) degradation of
intracellular phospholipid second messengers, e.g., phospha-
tidic acid, and thereby intracellular signal termination [132–
134]. The two known SPPs are structurally related to LPPs,
but hydropathy analysis suggests the presence of 8–10
transmembrane domains rather than 6 [135–138]. These
enzymes have predicted molecular masses of 46 and
49 kDa, respectively, and broad and partially overlapping
expression patterns [136–138]. Interestingly, SPPs are inhib-
ited by detergents such as Triton X-100 and show a marked
preference for substrates attached to protein carriers. Both
SPP1 and SPP2 specifically dephosphorylate S1P and localizeto the endoplasmic reticulum, their catalytic site is predicted
to face the luminal site of the endoplasmic reticulum [136–
138]. Cellular depletion of SPP1 by siRNA caused accumula-
tion of S1P within the cells and also in the medium,
indicating that SPP1 plays a role in regulating extracellular
S1P levels [137].
S1P lyase is a pyridoxal-5′-phosphate-dependent enzyme of
63 kDa with one transmembrane domain close to its N-terminus
[139,140]. The enzyme is located at the endoplasmic reticulum,
and the pyridoxal-5′-phosphate binding domain as well as the
catalytic site are exposed to the cytosol [141]. Expression of
S1P lyase mRNA transcripts was widespread in mouse tissues,
but did not always fully parallel enzyme activity. S1P lyase
expression and activity was very low in mouse brain and, in
agreement with previous reports, absent in platelets [141].
Obviously, S1P lyase contributes to the balance between
proapoptotic ceramide and antiapoptotic S1P, since overexpres-
sion of the enzyme enhanced ceramide levels and caused
ceramide-dependent apoptosis [142]. Accordingly, Drosophila
lacking S1P lyase displayed increased apoptosis in developing
embryos and diminished egg-laying [143]. Most interestingly,
these flies had specific abnormalities in dorsal longitudinal
flight muscles and a severe flight defect, which reveals the
importance of S1P lyase in metazoan development [143].
Reports about the phenotype of S1P lyase deficient mice are
awaited for the near future. Recent data demonstrate that S1P
lyase influences extracellular S1P levels, contributing to the
formation of S1P tissue gradients; this is reported in greater
detail below.
3.2. Role of SphK1 in generating extracellular S1P: signalling
inside-out
SphK activity is regulated both transcriptionally and post-
transcriptionally by a large number of agonists, among them
diverse GPCRs (e.g. muscarinic, formyl peptide, lysopho-
spholipid, bradykinin), receptor tyrosine kinases (PDGF, EGF),
cytokine and antigen receptors (for review, see [109,110,144]).
However, SphK1 has a substantial basal activity, and post-
transcriptional activation often leads to only moderate increases
in its enzymatic activity (discussed in [111]). It is becoming
increasingly clear that translocation to distinct subcellular
regions is an important mechanism by which SphK1 is
regulated [110,111,124] (Fig. 1). Artificial targeting of SphK1
to the endoplasmic reticulum or to the plasma membrane had a
major impact on its function [124,145]. Phorbol ester, tumour
necrosis factor-α, NGF or activation of muscarinic acetylcho-
line receptors induced a rapid translocation of SphK1 from the
cytosol to the plasma membrane [146–149]. Several reports
have shown that signalling via SphK1 can lead to S1P export
and activation of S1P-GPCRs. For example, SphK1 over-
expression in NIH 3T3 fibroblasts induced formation of stress
fibres and focal adhesions, inhibited migration, stimulated
proliferation and protected from apoptosis, and thus mimicked
actions of extracellular S1P [150]. Accordingly, stress fibre
formation induced by SphK1 overexpression required signal-
ling via G12/13, while proliferation and survival could not be
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its TrkA receptor induced translocation of SphK1 to the plasma
membrane and internalization of S1P1 and S1P5 [149]. Knock-
down of SphK1 by siRNA inhibited neurite extension induced
by NGF in dorsal root ganglion cells, while extracellular S1P
accelerated neurite extension by NGF in these cells, demon-
strating the importance of S1P-GPCR cross-activation in this
process [149]. SphK1 is known to be crucial for antigen
receptor signalling in mast cells [151], and it was shown that the
S1P2 receptor was required for degranulation [152]. Further-
more, platelet-derived growth factor (PDGF) induced SphK1
translocation to the plasma membrane at the leading edge of
migrating cells, and S1P1 was required for PDGF-stimulated
migration [153]. Although there are other examples for S1P
signalling inside-out, there are also data demonstrating an
interaction of S1P1 and PDGF receptors independently of
autocrine S1P secretion. Even S1P1 mutants defective in S1P
binding enhanced PDGF receptor signalling [154]. This cross-
talk is considered to be based on a receptor signalling platform
and sharing of G-protein subunits [155,156]. The mechanism by
which S1P can be exported remains largely unknown, although
the involvement of ABC transporters has been suggested at least
in platelets [157]. On the other hand, SphK1 can also be found
extracellularly, it was constitutively secreted by vascular
endothelial cells and found in mouse and human plasma
[158,159]. It should be noted that SphK1 in addition to
signalling inside-out also plays an intracellular role, like SphK2,
since it can be translocated to intracellular sites such as sites of
phosphatidic acid production [134], has a nuclear export
sequence that contributes to its cytosolic localization [160],
and several of its effects are not imitated by exogenous S1P
(e.g., [150]), see Fig. 1.
3.3. Role of S1P lyase in controlling extracellular S1P
gradients
Recently, it was shown that S1P lyase plays an important role
in maintaining a steep S1P concentration gradient between
blood and tissues, which is required for lymphocyte trafficking
[161] (commentary in [162]). The food colorant, 2-acetyl-4-
tetrahydroxybutylimidazole (THI), known for its immunosup-
pressive action, was shown to inhibit S1P lyase. In mice treated
with THI, S1P levels in thymus, spleen and lymph nodes were
greatly enhanced, while those in plasma, which under control
conditions were higher than those in lymphoid tissues, were not
much changed [161]. As a consequence, the S1P1 receptor was
internalized by interstitial fluid extracts from lymphoid tissue or
lymph of THI-treated mice. In addition, S1P1 was down-
regulated by plasma, but not by lymphoid tissue extracts of
control animals [161]. The S1P1 receptor mediates lymphocyte
egress and is internalized by the novel immunosuppressant,
FTY720 (see below). S1P lyase inhibition by THI as well as
siRNA downregulation of S1P lyase imitated this phenotype. A
model has been developed in which S1P lyase contributes to the
usually low S1P levels in lymphoid tissue, while the higher
plasma levels of S1P act as a chemoattractant for emigration of
lymphocytes [162]. Interestingly, FTY720, besides being asubstrate for sphingosine kinases, inhibited S1P lyase in vitro
and in vivo and slightly increased tissue S1P levels [163]. It was
suggested that this activity of FTY720, besides downregulation
of S1P1 by phosphorylated FTY720, may contribute to its
immunosuppressive action [163].
3.4. LPA metabolism: diverse pathways
There are several pathways that contribute to production of
LPA. For generation of bioactive LPA acting on GPCR, three
pathways, catalysed by extracellular enzymes, appear to play a
role: (1) deacylation of phosphatidic acid by PLA1 and PLA2,
(2) cleavage of lysophospholipids by lyso-PLD, and (3) mild
oxidation of low-density lipoproteins (for comprehensive
review, see [164,165]). Secretory type-II PLA2 and phospha-
tidic acid-selective PLA1 cleave surface-exposed phosphatidic
acid, which for example occurs in microvesicles shed from
activated inflammatory cells. The main source of extracellular
LPA, however, appears to be lyso-PLD-catalysed cleavage of
lysophospholipids such as LPC [166,167]. The lyso-PLD that
generates LPA has recently been found to be identical with the
cell motility-stimulating factor, autotaxin [168,169] (see
below). Another possibility for LPA production is phosphoryla-
tion of monoacylglycerol. Recently, an acylglycerol kinase was
described that had a diacylglycerol kinase catalytic domain but
differed from the known diacylglycerol kinases, and phos-
phorylated monoacylglycerol (preferentially 1-oleoyl-glycerol,
but also 2-arachidonyl-glycerol, an endocannabinoid) and
diacylglycerol to form LPA and phosphatidic acid, respectively
[170]. This enzyme was located at the mitochondria, and its
overexpression promoted formation and secretion of LPA.
However, data from autotaxin deficient mice illustrate the
prevailing dominance of this enzyme in production of bioactive
LPA, and therefore autotaxin is discussed in more detail below.
Degradation of extracellular LPA can be attributed to the
ectophosphatase activity of plasma membrane LPPs or acyla-
tion by LPA acyl transferases [129–132] (Fig. 2).
3.5. Production of extracellular LPA by autotaxin
Autotaxin was originally isolated as an autocrine chemotac-
tic factor from melanoma cells and was considered to be an
ecto-nucleotide pyrophosphatase/phosphodiesterase (reviewed
in [165]). Autotaxin occurs as a membrane-bound protein of
∼125 kDa with a single transmembrane domain close to the
cytosolic N-terminus, and as a soluble enzyme that is generated
from the former by proteolytic processing and secreted from
cells (Fig. 2). In 2002, it was demonstrated that autotaxin was
the long-searched lyso-PLD in plasma and serum that cleaved
LPC to form LPA [168,169]. The decisive contribution of
autotaxin to LPA production in plasma was recently demon-
strated by mice deficient in autotaxin [166,167]. Because
homozygous autotaxin-deficient mice died early during embry-
ogenesis, plasma levels of LPA were determined in hetero-
zygous mice, and found to be half as high as in control mice
[166,167]. In contrast, plasma S1P levels were not affected,
demonstrating that the in vitro observed ability of autotaxin to
Fig. 2. Generation and degradation of bioactive LPA. In contrast to S1P, bioactive LPA seems not to be secreted, instead, it is formed extracellularly by diverse
pathways (for review, see [164, 165]). LPA can be generated by deacylation of phosphatidic acid (PA), catalysed by phosphatidic acid-selective PLA1 or secretory
type-II PLA2. For this, phosphatidic acid has to be transferred to the outer leaflet of the plasma membrane as it is the case in shed microvesicles. A major source of
extracellular LPA is cleavage of lysophospholipids, predominantly LPC, by a lyso-PLD named autotaxin (ATX) [166–169]. This enzyme is generated as a membrane
protein, further processed by proteolysis and secreted as a soluble protein. LPA is furthermore formed during de novo phospholipid synthesis at the endoplasmic
reticulum by conjugation of phosphatidyl glycerol (PG) and acyl-CoA. Recently, an acylglycerol kinase expressed in mitochondria was described that phosphorylated
monoacylglycerol (MAG) and diacylglycerol (DAG) and promoted LPA generation and secretion [170]. LPA is not only an agonist at G-protein-coupled receptors, but
also activates the transcription factor, peroxisome proliferator-activated receptor-γ (PPARγ) [93]. Degradation of LPA occurs by dephosphorylation, catalysed by lipid
phosphate phosphatases (LPP), or by acylation, catalysed by LPA acyl transferases (LPAAT) [129–132,164]. For additional references, see text.
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a role in vivo. Mice with homozygous autotaxin deficiency died
around embryonic day 10 with major vascular defects in yolk
sac and embryo, and also had allantois malformation, neural
tube defects and asymmetric headfolds [166,167]. This
phenotype is much more severe than that of mice deficient in
either LPA1, LPA2 or LPA3 receptor [172–174]. LPA1 deletion
caused defects in craniofacial morphogenesis, brain develop-
ment and olfaction, while LPA2 knockout did not lead to
obvious defects. Mice deficient in LPA3 were recently reported
to be born with ∼50% reduced litter sizes, which could be
traced back to downregulation of cyclooxygenase-2 in LPA3-
deficient uteri during preimplantation, leading to delayed
implantation and altered positioning of embryos. However,
the born mice were reported to be grossly normal [174]. In
contrast, the severe phenotype of autotaxin deficiency demon-strates that this enzyme is decisive for LPA production during
embryogenesis, thereby affecting the signalling of LPA in
general [166]. Interestingly, autotaxin deficiency strongly
resembled the phenotype of G13 knockout mice, showing the
importance of this G-protein in signalling by LPA-GPCR [166].
Transcriptional regulation of autotaxin secretion was for
example shown in adipocytes, in which autotaxin mRNA as
well as autotaxin activity and LPA levels in culture supernatants
were upregulated during differentiation [175]. Furthermore,
autotaxin promoted the differentiation of preadipocytes and was
substantially overexpressed in adipose tissue of obese diabetic
(db/db) mice, but not in mice treated with high-fat diet or in
mice with streptozotocin-induced diabetes [175,176]. However,
autotaxin expression was downregulated by the insulin-
sensitizing drug, rosiglitazone, and, most importantly, signifi-
cantly upregulated in patients exhibiting both insulin resistence
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autotaxin might play a role in adipocyte insulin resistance,
rather than in obesity or hyperglycaemia [176]. Autotaxin was
furthermore found to be overexpressed in frontal cortex of
patients with Alzheimer-type dementia [177], however, its
function in dementia is currently unknown.
4. Emerging lysophospholipid pharmacology
Since the early days of testing compounds in which the
glycerol backbone of LPA was replaced by serine, tyrosine or
ethanolamine for interaction with LPA receptors, the area of
lysophospholipid pharmacology has seen much progress and
interesting developments. The search for lysophospholipid
receptor subtype-selective drugs is supported by homology
modelling that greatly enhanced our understanding on how
GPCRs recognize lipid ligands [41,178–182]. In 2002, it was
reported by two groups that the novel immunosuppressive,
FTY720, interacts with S1P-GPCRs [50,51]. It is now known
that FTY720 is phosphorylated by sphingosine kinase in vivo
and then acts as an agonist with low nanomolar affinity on S1P1,
S1P3, S1P4 and S1P5, but not S1P2 receptors. Phosphorylation
of FTY720 was required for its immunosuppressive action,
since it did not cause lymphopenia in SphK2 deficient mice
[126,128], while interestingly SphK1 was not required [125].
Furthermore, the immunosuppressive action of FTY720 was
mimicked by FTY720-phosphonate which cannot be depho-
sphorylated [50]. This indicates that the additional effects of
non-phosphorylated FTY720, such as inhibition of S1P lyase
[163] and antagonism at cannabinoid CB1 receptors [183],
which both require low micromolar concentrations of FTY720,
have only little impact on its immunosuppressive action.
The S1P1 receptor was identified as the major target
mediating FTY720-induced lymphopenia, since in mice
whose haematopoietic cells lack S1P1, T and B lymphocytes
were unable to exit lymphoid tissues [31]. FTY720 treatment
downregulated S1P1, thereby mimicking S1P1 deficiency [31,
49]. Furthermore, also the S1P1 selective agonist, SEW2871,
inhibited lymphocyte recirculation in mice [37,184]. It is now
clear that there is a S1P concentration gradient between plasma
and extracellular fluid of lymphoid tissue that is created by
differential actions of S1P lyase and sphingosine kinase, and
that plasma S1P acts as a chemoattractant on lymphocytes in
lymphoid tissues. The gradient is sensed by the S1P1 receptor
that mediates migration and is usually upregulated in lympho-
cytes within lymphoid tissue and downregulated in lympho-
cytes within blood [159,161,162,185]. Since FTY720 does not
generally impair T- and B-cell proliferation and functions, it
represents a novel mode of immunosuppressive action, which
might be useful in transplantation as well as multiple sclerosis
or autoimmune diabetes, leaving crucial functions of the
immune system intact (reviewed in [21]). T lymphocytes
furthermore contribute to ischemia–reperfusion injury, and
FTY720 as well as SEW2871 reduced the damage caused by
ischemia–reperfusion in liver and kidney [186–189]. Moreover,
S1P1 downregulation in other cell types may cause additional
effects. Accordingly, FTY720 inhibited S1P- and vascularendothelial growth factor-induced angiogenesis, in which S1P1
plays a role, and impeded primary and metastatic tumour
growth in a murine model of melanoma [190].
Considering the molecular effect of FTY720-phosphate, and
also that of SEW2871, it is obvious that S1P1 activation is
followed by downregulation, the latter being the clinically
important effect. This could be interpreted as super-agonist
activity of FTY720-phosphate and SEW2871. On the other
hand, S1P1 is obviously also downregulated in the high S1P
level environment of plasma [161], suggesting that this receptor
might be prone for up- and downregulation. Interestingly, the
S1P1 receptor has a high constitutive activity, and recently, an
inverse agonist for S1P1 has been described [154]. It is an
intriguing question how this inverse agonist would affect
lymphocyte trafficking. Interestingly, it was demonstrated very
recently that a S1P1 antagonist did not cause lymphopenia
[191]. Obviously, there are still open questions with regard to
regulation of lymphocyte trafficking by S1P1.
Other actions of FTY720 correlate with activation but not
downregulation of S1P-GPCRs. The undesired effect of
bradycardia that is observed during the first days of FTY720
treatment is mediated by FTY720-phosphate's activation of
S1P3 [37]. In mouse aorta, FTY720 induced NO synthase
activation and vasodilatation via S1P3 [192]. Mimicking other
effects of S1P on endothelial cells, FTY720 stimulated ERK
and Akt, adherens junction assembly, survival and migration
and reduced vascular permeability in vivo [193]. In contrast, the
recently reported S1P1 antagonist strongly enhanced capillary
leakage in lung [191]. Regulation of the endothelial barrier
function is of particular medicinal interest as its impairment
plays a role in many pathological conditions.
SEW2871, the first compound highly specific for a S1P
receptor subtype, was identified by high-throughput screening
[37,184]. Interestingly, this compound lacks a phosphate group
(for chemical structures, see [182]). Its EC50 for stimulating
GTPγS binding by S1P1 was ∼13 nM, while that of S1P was
∼0.4 nM. SEW2871 was a full agonist, stimulating Akt, ERK
and cell migration. In vivo-application of SEW2871 induced
lymphopenia in mice with a plasma EC50 of ∼2 μM, but had no
influence on heart rate, which is regulated by S1P3 [37]. In
ischemia–reperfusion damage in mouse kidney, a dose of
10 mg/kg SEW2871 was required for reduction of elevated
plasma creatinine by ∼70%; however, a nearly 50% reduction
was already achieved with 0.1 mg/kg SEW2871. Nevertheless,
FTY720 was much more potent [188]. A putative S1P3 receptor
antagonist, BML-241, was identified by searching a three-
dimensional compound database with a pharmacophore model
of S1P [194], however, BML-241 is poorly characterized. A
specific S1P2 receptor antagonist, JTE-013, was used to prove
the inhibitory action of S1P2 on cell migration [33,195], and to
show that S1P2 mediates contraction of coronary artery smooth
muscle cells [196].
Recently, a series of aryl amide compounds was presented
which were more or less receptor subtype-selective; the lead
compound, VPC23019, was a competitive antagonist at S1P1
and S1P3 [197]. Ki values for VPC23019 in radioligand binding
assays at S1P1 and S1P3 were in the low nanomolar range, and
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zation. Small structural changes converted the molecule into an
agonist. Furthermore, VPC23019 as all compounds of this series
behaved as agonist at S1P4 and S1P5, but had no activity at S1P2
[197]. In mouse vascular endothelial cells expressing S1P2 and
S1P3, but not S1P1, VPC23019 inhibited S1P-stimulated Rac
activation, migration and vascular tube formation, while JTE-
013 enhanced these effects, indicating that S1P2 and S1P3
receptors have an opposing influence on these endothelial
parameters [198]. For detailed discussion of ligand structure–
activity relationships at S1P-GPCRs, see [182].
There are several compounds available that exhibit more or
less selective antagonism at LPA-GPCRs. Dioctylglycerol
pyrophosphate (DGPP 8:0) is a short-chain derivative of
diacylglycerol pyrophosphate, which apparently is a signalling
molecule in yeast and plants but not in higher animals (reviewed
in [199]). It was demonstrated that DGPP 8:0 acts as a
competitive antagonist at human LPA receptors, inhibiting
preferentially LPA3 (IC50 ∼100 nM), and also LPA1 (IC50
∼7 μM), but not LPA2 [180,200]. The preference of DGPP 8:0
for LPA3 was recently confirmed [201]. Platelet activation
induced by LPA, but not by other platelet stimuli, was inhibited
by DGPP 8:0, but not by DGPP 18:0, in a competitive manner
with an IC50 of ∼2.5 μM [202]. Although platelets express
LPA1, LPA2 and LPA3, the inhibitory action of DGPP
implicates the involvement of LPA3, and probably also LPA1,
in platelet shape change induced by LPA. DGPP 8:0 at 20 μM
furthermore fully blocked platelet activation by mildly oxidated
low density lipoproteins and by homogenates of lipid-rich core
isolated from soft arteriosclerotic plaques, indicating that
predominantly the LPA species, that were identified in this
material, were involved in platelet activation by lipid-rich core
[202].
A differential interaction with LPA-GPCRs was observed
with fatty alcohol phosphates (FAP) with carbon chain lengths
between 10 and 14 [203]. FAP-12 (dodecyl-FAP) activated
LPA2, thereby inducing [Ca
2+]i increases with an EC50 of
∼700 nM, while it antagonized LPA3 in a competitive manner,
inhibiting LPA-induced [Ca2+]i increases with an IC50 of
∼90 nM. This compound was a weak antagonist at LPA1 and
did not interfere with S1P-GPCRs [203]. A compound rather
non-selective for LPA receptor subtypes is Ki16425 (for
structure, see [182], which was identified by high-throughput
screening of 150,000 compounds for inhibition of LPA-induced
[Ca2+]i increases [201]. This compound inhibited LPA-
stimulated inositol phosphate production and GTPγS binding
with Ki values of 0.2–0.9 μM at LPA1 and LPA3, while its Ki
values at LPA2 were around 6 μM [201]. Ki16425 did not affect
responses to S1P, platelet-activating factor, bradykinin or
platelet-derived growth factor, and therefore might be useful
as general LPA-GPCR inhibitor. A similar preference for LPA1
and LPA3 was observed with VPC12249 [204]. O-methylphos-
phothionate (OMPT), a LPA3-selective agonist [205], aggra-
vated ischemia–reperfusion injury in mouse kidney, while the
LPA1/3 antagonist, VPC12249, reduced tubular injury, ischemic
necrosis in outer medulla, and leukocyte infiltration [206]. LPA
itself inhibited renal injury at low concentrations, but aggra-vated the damage at higher concentrations, suggesting differ-
ential effects of LPA-GPCR subtypes in renal ischemia–
reperfusion. The data observed with the inhibitors support the
hypothesis that LPA3 acts deleterious in this disease process
[206]. For detailed discussion of structure–activity relationships
of ligands at LPA-GPCRs, see [180,182]. Since most com-
pounds that interact with LPA-GPCRs, except Ki16425, have a
phosphate group that can be subject to dephosphorylation, a
novel strategy focuses on metabolically stabilized LPA
analogues such as phosphonates, phosphorothioates, phospho-
nothioates and fluorophosphonates [207]. These compounds
affect LPA-GPCRs as well as LPA metabolizing enzymes [207].
Recently, a novel approach to pharmacological intervention
at S1P-GPCRs, an anti-S1P antibody, was introduced [208]
(commentary in [209]). Based on the concept that S1P promotes
tumour proliferation, invasion and angiogenesis, the antibody
was tested on transplanted mouse tumours. Proliferation of
various tumour types, e.g., lung, breast, melanoma and ovarian
cancers, was effectively retarded by the antibody. Furthermore,
tumour-associated angiogenesis, plasma levels of interleukin-6,
-8 and vascular endothelial growth factor, and the ability of S1P
to protect tumour cells from apoptosis, was reduced by the anti-
S1P antibody [208]. Other than sphingosine kinase inhibitors,
which also successfully inhibit tumour cell growth [115,210],
the anti-S1P antibody will attack S1P from all sources.
5. Concluding remarks
Research of the past decade has demonstrated that many
important physiological and pathophysiological processes are
regulated by lysophospholipids. As summarized in recent
reviews, S1P and LPA play a role in the immune system
[7,20,211–214], cardiovascular system [215–222], nervous
system [223,224] and cancer [101,225]. G protein-coupled
lysophospholipid receptors and the enzymes of lysophospho-
lipid metabolism are therefore promising targets for medicinal
interventions. Potential indications for drugs acting on lysopho-
spholipid GPCRs have been suggested [8]. It remains a
challenge to understand the complex interplay of lysopho-
spholipid formation and degradation and receptor downregula-
tion, recycling and cross-talk.
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